- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload
Subhash K. Das1, Jessica DesAulniers1, Jason R. B. Dyck3, Zamaneh Kassiri2 andGavin Y. Oudit1,2,*
DOI: 10.1111/liv.12893
This article is protected by copyright. All rights reserved.
Issue
Cover image for Vol. 35 Issue 7
Liver International
1 Department of Medicine, University of Alberta, Edmonton, Canada
2 Department of Physiology, University of Alberta, Edmonton, Canada
3 Department of Pediatrics and Pharmacology, University of Alberta, Edmonton, Canada
* Address for Correspondence:
Gavin Y. Oudit, MD, PhD, FRCP(C)
Department of Medicine, Faculty of Medicine and Dentistry
University of Alberta, Edmonton,
Alberta, T6G 2S2, Canada
Phone: 780-407-8569; Fax: 780-407- 6452
[email protected]
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.12893
Iron-overload;lipid peroxidation;hepatic fibrosis;inflammation;oxidative stress;resveratrol
Abstract
Background and Aims
Abnormal iron metabolism and hepatic iron-overload is a major cause of liver injury and in the development of chronic liver diseases. Iron-overload mediated liver disease leads to end-stage cirrhosis and/or hepatocellular carcinoma.
Methods
Using a genetic hemochromatosis (hemojuvelin knockout mice) and non-genetic (secondary iron-overload) murine models of hepatic iron-overload we elucidated the mechanism of hepatic iron injury and the therapeutic effects of resveratrol.
Results
Hepatic iron-overload was associated with hepatosplenomegaly, increased oxidative stress, hepatic fibrosis, and inflammation, and a pro-apoptotic state which was markedly corrected by resveratrol therapy. Importantly our aging studies with the hemojuvelin knockout mice showed advanced liver disease in association with steatosis in the absence of a diabetic state which recapitulates the essential pathological features seen in clinical iron-overload. Chronic hepatic iron-overload showed increased nuclear localization of acetylated Forkhead fox-O-1 (FoxO1) transcription factor while resveratrol dietary intervention reversed the acetylation of FoxO1 in association with increased SIRT1 levels which together with its pleotropic antioxidant properties are likely key mechanisms of its therapeutic action. Importantly, resveratrol treatment did not affect the degree of hepatic iron-overload but rather direct protects the liver from iron-mediated injury.
Conclusions
Our findings illustrate a novel and definitive therapeutic action of resveratrol and represent an economically feasible therapeutic intervention to treat hepatic iron-overload and liver disease.
This article is protected by copyright. All rights reserved.
|
|